FCGR3A and neoplasm: Trastuzumab and pertuzumab share the ability to engage the NK cell activating FcγRIIIA (CD16) receptor and induce specific killing of the opsonized HER2+ tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC), as demonstrated in several in vitro and in vivo studies (6–9).